408 related articles for article (PubMed ID: 22908014)
21. 5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells.
Taylor V; Wong M; Brandts C; Reilly L; Dean NM; Cowsert LM; Moodie S; Stokoe D
Mol Cell Biol; 2000 Sep; 20(18):6860-71. PubMed ID: 10958682
[TBL] [Abstract][Full Text] [Related]
22. Phosphatases: the new brakes for cancer development?
Zhang Q; Claret FX
Enzyme Res; 2012; 2012():659649. PubMed ID: 22121480
[TBL] [Abstract][Full Text] [Related]
23. B cell expression of the SH2-containing inositol 5-phosphatase (SHIP-1) is required to establish anergy to high affinity, proteinacious autoantigens.
Akerlund J; Getahun A; Cambier JC
J Autoimmun; 2015 Aug; 62():45-54. PubMed ID: 26152931
[TBL] [Abstract][Full Text] [Related]
24. Transforming growth factor β (TGF-β) receptor signaling regulates kinase networks and phosphatidylinositol metabolism during T-cell activation.
Cattley RT; Lee M; Boggess WC; Hawse WF
J Biol Chem; 2020 Jun; 295(24):8236-8251. PubMed ID: 32358062
[TBL] [Abstract][Full Text] [Related]
25. Putting on the Brakes: Regulatory Kinases and Phosphatases Maintaining B Cell Anergy.
Franks SE; Cambier JC
Front Immunol; 2018; 9():665. PubMed ID: 29681901
[TBL] [Abstract][Full Text] [Related]
26. Src Homology 2 Domain-Containing Inositol 5'-Phosphatase Ameliorates High Glucose-Induced Extracellular Matrix Deposition via the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway in Renal Tubular Epithelial Cells.
Li F; Li L; Hao J; Liu S; Duan H
J Cell Biochem; 2017 Aug; 118(8):2271-2284. PubMed ID: 28075049
[TBL] [Abstract][Full Text] [Related]
27. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Seda V; Mraz M
Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
[TBL] [Abstract][Full Text] [Related]
28. Phosphoinositide lipid phosphatases: natural regulators of phosphoinositide 3-kinase signaling in T lymphocytes.
Harris SJ; Parry RV; Westwick J; Ward SG
J Biol Chem; 2008 Feb; 283(5):2465-9. PubMed ID: 18073217
[TBL] [Abstract][Full Text] [Related]
29. Regulation of Hematopoietic Cell Development and Function Through Phosphoinositides.
Elich M; Sauer K
Front Immunol; 2018; 9():931. PubMed ID: 29780388
[TBL] [Abstract][Full Text] [Related]
30. Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation.
Krasilnikov MA
Biochemistry (Mosc); 2000 Jan; 65(1):59-67. PubMed ID: 10702641
[TBL] [Abstract][Full Text] [Related]
31. A Precision B Cell-Targeted Therapeutic Approach to Autoimmunity Caused by Phosphatidylinositol 3-Kinase Pathway Dysregulation.
Franks SE; Getahun A; Cambier JC
J Immunol; 2019 Jun; 202(12):3381-3393. PubMed ID: 31076529
[TBL] [Abstract][Full Text] [Related]
32. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
Iyengar S; Clear A; Bödör C; Maharaj L; Lee A; Calaminici M; Matthews J; Iqbal S; Auer R; Gribben J; Joel S
Blood; 2013 Mar; 121(12):2274-84. PubMed ID: 23341541
[TBL] [Abstract][Full Text] [Related]
33. TAPP Adaptors Control B Cell Metabolism by Modulating the Phosphatidylinositol 3-Kinase Signaling Pathway: A Novel Regulatory Circuit Preventing Autoimmunity.
Jayachandran N; Mejia EM; Sheikholeslami K; Sher AA; Hou S; Hatch GM; Marshall AJ
J Immunol; 2018 Jul; 201(2):406-416. PubMed ID: 29884706
[TBL] [Abstract][Full Text] [Related]
34. PI3K-p110δ contributes to antibody responses by macrophages in chronic lymphocytic leukemia.
Enya Chen YC; Burgess M; Mapp S; Mollee P; Gill D; Blumenthal A; Saunders NA
Leukemia; 2020 Feb; 34(2):451-461. PubMed ID: 31462739
[TBL] [Abstract][Full Text] [Related]
35. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
Lannutti BJ; Meadows SA; Herman SE; Kashishian A; Steiner B; Johnson AJ; Byrd JC; Tyner JW; Loriaux MM; Deininger M; Druker BJ; Puri KD; Ulrich RG; Giese NA
Blood; 2011 Jan; 117(2):591-4. PubMed ID: 20959606
[TBL] [Abstract][Full Text] [Related]
36. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
37. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.
So L; Yea SS; Oak JS; Lu M; Manmadhan A; Ke QH; Janes MR; Kessler LV; Kucharski JM; Li LS; Martin MB; Ren P; Jessen KA; Liu Y; Rommel C; Fruman DA
J Biol Chem; 2013 Feb; 288(8):5718-31. PubMed ID: 23275335
[TBL] [Abstract][Full Text] [Related]
38. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses.
Durand CA; Hartvigsen K; Fogelstrand L; Kim S; Iritani S; Vanhaesebroeck B; Witztum JL; Puri KD; Gold MR
J Immunol; 2009 Nov; 183(9):5673-84. PubMed ID: 19843950
[TBL] [Abstract][Full Text] [Related]
39. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
Herman SE; Gordon AL; Wagner AJ; Heerema NA; Zhao W; Flynn JM; Jones J; Andritsos L; Puri KD; Lannutti BJ; Giese NA; Zhang X; Wei L; Byrd JC; Johnson AJ
Blood; 2010 Sep; 116(12):2078-88. PubMed ID: 20522708
[TBL] [Abstract][Full Text] [Related]
40. Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors.
Freeburn RW; Wright KL; Burgess SJ; Astoul E; Cantrell DA; Ward SG
J Immunol; 2002 Nov; 169(10):5441-50. PubMed ID: 12421919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
